The FDA approved Nuvation Bio’s Ibtrozi for treating ROS1-positive non-small cell lung cancer, marking the company's entry into a competitive market dominated by Pfizer, Bristol Myers Squibb, and Roche. Ibtrozi demonstrated strong response rates and favorable safety profiles in clinical trials, showing promise for patients with brain metastases. The approval positions Nuvation as a challenger in targeted lung cancer therapies, potentially altering market dynamics.